Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/115152
Title: Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial
Authors: Zaninetti, Carlo
Gresele, Paolo
Bertomoro, Antonella 
Klersy, Catherine
De Candia, Erica
Veneri, Dino 
Barozzi, Serena
Fierro, Tiziana
Alberelli, Maria Adele
Musella, Valeria
Noris, Patrizia
Fabris, Fabrizio 
Balduini, Carlo L
Pecci, Alessandro
Issue Date: Mar-2020
Journal: Haematologica 
Abstract: 
Patients with inherited thrombocytopenias often require platelet transfusions to raise their platelet count before surgery or other invasive procedures; moreover, subjects with clinically significant spontaneous bleeding may benefit from an enduring improvement of thrombocytopenia. The hypothesis that thrombopoietin-mimetics can increase platelet count in inherited thrombocytopenias is appealing, but evidence is scarce. We conducted a prospective, phase II clinical trial to investigate the efficacy of the oral thrombopoietin-mimetic eltrombopag in different forms of inherited thrombocytopenia. We enrolled 24 patients affected by MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked thrombocytopenia/ Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related thrombocytopenia. The average pre-treatment platelet count was 40.4 ×109/L. Patients received a 3- to 6-week course of eltrombopag in a dose-escalated manner. Of 23 patients evaluable for response, 11 (47.8%) achieved a major response (platelet count >100 ×109/L), ten (43.5%) had a minor response (platelet count at least twice the baseline value), and two patients (8.7%) did not respond. The average increase of platelet count compared to baseline was 64.5 ×109/L (P<0.001). Four patients with clinically significant spontaneous bleeding entered a program of long-term eltrombopag administration (16 additional weeks): all of them obtained remission of mucosal hemorrhages, with the remission persisting throughout the treatment period. Treatment was globally well tolerated: five patients reported mild adverse events and one patient a moderate adverse event. In conclusion, eltrombopag was safe and effective in increasing platelet count and reducing bleeding symptoms in different forms of inherited thrombocytopenia. Despite these encouraging results, caution is recommended when using thrombopoietinmimetics in inherited thrombocytopenias predisposing to leukemia. ClinicalTrials.gov identifier: NCT02422394.
URI: http://hdl.handle.net/20.500.12857/115152
DOI: 10.3324/haematol.2019.223966
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

5
Last Week
2
Last month
checked on May 2, 2021

SCOPUSTM   
Citations

5
checked on Sep 4, 2020

WEB OF SCIENCETM
Citations

31
checked on Dec 6, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.